Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-19T06:23:34.892Z Has data issue: false hasContentIssue false
  • English
  • Français

Escitalopram in Treatment of Sleep Disturbances in Major Depressive Disorder

Published online by Cambridge University Press:  16 April 2020

N. Zivkovic ,
G. Djokic ,
D. Pavicevic  and
V. Ilic
N. Zivkovic
Affiliation:
Emergency Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
G. Djokic
Affiliation:
Consultative Neurology, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
D. Pavicevic
Affiliation:
Emergency Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
V. Ilic
Affiliation:
Emergency Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Major depressive disorder (MDD) is common and severe affective disorder with sleep disturbances and non-bizarre delusions which are organized in permanent and unshakeable delusional system. Neurobiological basis of MDD is still completely unknown, but significant role has serotoninergic and noradrenergic neuronal systems. Escitalopram is highly potent and highly selective serotonin re-uptake inhibitor.

Purpose of this study was to estimate efficacy of the escitalopram in treatment of sleep disturbances in MDD.

Methods:

This prospective clinical study included 95 patients diagnosed by ICD-10 criteria for MDD, who are randomly divided into control (30 patients) and experimental group (65 patients). Patients were observed for 6 months in hospital and outpatients conditions, according to specially designed protocol, which included Hamilton Depression Rating Scale (HAMD) and Leeds Sleeping Evaluation Questionnaire (LSEQ). Control group was treated with maprotiline (75-150 mg/24h) and experimental group with escitalopram (10-20 mg/24h).

Results:

Escitalopram therapy influenced on HAMD score with high statistical significance vs. maprotiline, p=0.000. Escitalopram therapy improves LSEQ score after 6 months in comparison to maprotiline therapy with high statistical significance p=0.000. Percentage of adverse effects is significantly lower in escitalopram (10.76%) than in maprotiline (26.67%) group.

Conclusion:

Escitalopram has significantly better efficacy and lower adverse effects rate in treatment of depressive symptoms and sleep disturbances in MDD patients comparing to maprotiline.

Type
P01-244
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E632
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.